CASTLE BIOSCIENCES INC — Director's Dealing 2020

Oct 15, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CASTLE BIOSCIENCES INC (CSTL)
CIK: 0001447362
Period of Report: 2020-10-13

Reporting Person: Stokes Frank (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-10-13	Common Stock	M	13000	$2.39	Acquired	14886	Direct
2020-10-13	Common Stock	S	13000	$54.791	Disposed	1886	Direct
2020-10-14	Common Stock	M	13000	$2.39	Acquired	14886	Direct
2020-10-14	Common Stock	S	3400	$53.064	Disposed	11486	Direct
2020-10-14	Common Stock	S	8300	$54.58	Disposed	3186	Direct
2020-10-14	Common Stock	S	1300	$55.134	Disposed	1886	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-10-13	Stock option (right to buy)	$2.39	M	13000	Disposed	2028-05-09	Common Stock (13000.0)	Direct
2020-10-14	Stock option (right to buy)	$2.39	M	13000	Disposed	2028-05-09	Common Stock (13000.0)	Direct

Footnotes

F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020.

F2: This transaction was executed in multiple trades at prices ranging from $54.280 to $55.200, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: This transaction was executed in multiple trades at prices ranging from $52.810 to $53.780, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: This transaction was executed in multiple trades at prices ranging from $54.105 to $55.100, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F5: This transaction was executed in multiple trades at prices ranging from $55.115 to $55.140, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F6: The option is exercisable immediately, in whole or in part, conditioned upon the Reporting Person entering into a restricted stock purchase agreement with respect to any unvested shares. 25% of the 133,137 shares originally subject to the option vested on December 4, 2018, and the remaining shares vest in 36 equal monthly installments thereafter.